Physician profile
Belinda L Childs
NPI 1609969757
$6,861.32
in general payments reported to CMS, 2019-2025
24 companies · $1,207 in 2025
The $1,207 reported for 2025 was more than what 91% of Clinical Nurse Specialist providers received nationally (typical 2025 total: $150).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,087 · 2022: $1,132 · 2023: $1,051 · 2024: $1,385 · 2025: $1,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,433 · Consulting Fee: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,432.71 |
| Consulting Fee | $210.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $1,641.64 | 2021-2024 | |
| Lilly USA, LLC | $907.41 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $758.53 | 2021-2025 | Rybelsus, Ozempic |
| Insulet Corporation | $585.07 | 2024-2025 | Omnipod |
| Dexcom, INC. | $579.79 | 2021-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $519.53 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $382.31 | 2023-2025 | |
| Medtronic, INC. | $222.35 | 2021-2025 | Minimed 780g, Intellis Adaptivestim |
| Embecta Corp. | $219.23 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.98 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $190.03 | 2021-2025 | Wainua |
| Xeris Pharmaceuticals, INC. | $151.62 | 2021-2025 | Gvoke Hypopen |
| Cequr Corporation | $108.47 | 2024 | Cequr Simplicity |
| Nevro Corp. | $91.57 | 2022 | |
| Corcept Therapeutics | $82.00 | 2025 | Korlym |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $48.14 | 2021 | |
| Abbvie INC. | $33.76 | 2023 | |
| Amgen INC. | $26.71 | 2022 | |
| Sequel Med Tech, LLC | $21.89 | 2025 | Twiist |
| Zealand Pharma US, INC. | $20.22 | 2022 | |
| Tandem Diabetes Care, INC. | $17.61 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Becton, Dickinson and Company | $16.23 | 2021 | |
| Ascensia Diabetes Care US INC. | $15.96 | 2022 | |
| Merck Sharp & Dohme LLC | $13.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Belinda Childs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.